Dr. Hagenkord serves as chief medical officer for 23andMe where she is responsible for health product strategy and medical affairs. Dr. Hagenkord is a board-certified pathologist and was the first physician to complete fellowships in both pathology informatics and molecular genetic pathology. She has specialized in the design, validation, and implementation of massively parallel testing technologies for the clinical laboratory. Prior to joining 23andMe, Dr. Hagenkord served as Senior Vice President and Chief Medical Officer at Invitae Corporation, Complete Genomics and iKaryos Diagnostics, which she also founded. Dr. Hagenkord has also served as an Associate Professor of Pathology at Creighton University School of Medicine, the Director of Molecular Pathology and Clinical Genomics at Creighton Medical Laboratories, and as a pathologist at Deltagen, Inc.
Dr. South is board certified in clinical cytogenetics by the American Board of Medical Genetics and Genomics (ABMGG). Prior her position at 23andMe, she was an Associate Professor in the Department of Pathology at the University of Utah. While there, Dr. South also served as a medical director at ARUP Laboratories, oversaw the Cytogenetic and Genomic Microarray Laboratories and directed the ABMGG clinical cytogenetics training program at the University of Utah. She was also the CLIA lab director for Lineagen, and still acts as a consultant for Lineagen.
Dr. Jeffrey Pollard is primarily responsible for maintaining the clinical integrity of the 23andMe service. In addition, Dr. Pollard helps to advance the integration of personal genomics into the modern medical environment through educational initiatives and strategic engagement with integral members of the healthcare system. He has over a decade of hands-on clinical experience including owning and operating a multi-center medical practice and serving as a regional educator for the pharmaceutical company Allergan. Prior to joining 23andMe, he was the Medical Director for HealthTap and continues to be an advisor to innovative digital health companies.
Ms. Gordon is a board certified genetic counselor with more than 15 years of clinical and research experience in neurology, oncology, and genetics. She has been working in the field of personalized medicine for the past 8 years. Erynn joined 23andMe in 2015 as Director of Clinical Development to deepen engagement with the medical community as well as lead strategic initiatives related to clinical applications. In her previous roles, Erynn served as a bridge between the commercial and clinical sides of Invitae and as the Director of Genetic Counseling at the Coriell Institute for Medical Research where she helped build and manage the Coriell Personalized Medicine Collaborative, a research initiative aimed at evaluating the utility of personalized medicine.
Dr. Kim leads education initiatives and strategy at 23andMe. Prior to joining 23andMe, Dr. Kim was Medical Director at IntraMed where she delivered content-rich, clinically meaningful CME programs across all therapeutic areas for pharmaceutical and medical device companies. At Kaiser Permanente in Northern California, Dr. Kim developed and implemented the region-wide population management program. She also worked as a primary care pharmacist optimizing therapeutic outcomes for individual patients with chronic conditions.
Mr. Jacobs leads the 23andMe NGS assay, the high-throughput laboratory protocols, automation systems, LIMS and primary/secondary bioinformatic analysis. Prior to joining 23andMe, Mr. Jacobs was a senior member of the bioinformatics group at Invitae. He served on the strategic team for future products, lead teams to develop novel methods to interrogate challenging regions of regions of the genome, improve statistical models to detect complex genetic variations, and develop new technologies to reduce cost and increase throughput of assays and bioinformatics pipelines. Mr. Jacobs served for eight years at the Cancer Genomics Laboratory at the National Cancer Institute with increasing levels of responsibility, ultimately as Direction of Bioinformatics and Scientific Operations.
Dr. Eggington is assisting 23andMe in building a world-class next generation sequence variant classification pipeline for accurate and efficient assignment of disease causing mutations. Being the world’s first commercial diagnostic laboratory variant specialist, Dr. Eggington has been at the forefront of defining this rapidly growing scientific specialty. Dr. Eggington specializes in the initial classification of novel genetic variants, as well as the accurate reclassification of Variants of Uncertain Significance through optimized research methods. Prior to joining 23andMe, Dr. Eggington served as Courtagen Life Sciences’ Senior Director of Variant Sciences specializing in pediatric and neurological diseases. Before that, Dr. Eggington built and directed Myriad Genetic Laboratories’ genetic Variant Classification Program. Under her leadership, Myriad’s program became the industry leading variant program in hereditary cancer genetic testing.
Receive important updates, notices about new features and information about upcoming educational programs and engagement opportunities.